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Bleeding Avoidance StrategiesI greatly appreciate the interest of Dr. Woronow in
my recent study published in the Journal (1). Prot-
amine binds with heparin or low-molecular-weight
heparin to form a stable ion pair with no anticoagu-
lant activity. This compound is routinely used during
cardiopulmonary bypass surgery and is also admin-
istered to reverse the effect of heparin in patients in
stable condition after invasive cardiac catheterization
(e.g., post-transplant evaluation, fractional ﬂow
reserve estimation not requiring percutaneous coro-
nary interventions [PCIs]). Protamine, as mentioned
by the author, is not only important to reverse anti-
coagulation in case of major bleeding after PCI, but it
is also crucial in the uncommon event of cardiac or
coronary perforation during procedures that require
large doses of heparin (2).
There are several reasons that protamine cannot be
routinely used to avoid bleeding after PCI. First, the
allergic reactions to protamine are not uncommon
and can lead to serious anaphylaxis. Second, even
though protamine has been shown to be safe in small
series, case-control, and randomized studies, its
usefulness has not been proven in large contempo-
rary randomized trials (3). Third, its safety has been
tempered with case reports of ischemic complications
in patients treated with protamine (4). Fourth, the
use of the radial artery for access has diminished theutility of protamine reversal in favor of radial artery
patency requiring anticoagulation with heparin.
The role of protamine should be explored further,
and larger, randomized trials need to be planned. In
the meantime, patient selection for use of protamine
is important. Patients with seafood allergies or pre-
vious use of protamine should not be given this drug.
However, patients at very high risk of bleeding (e.g.,
elderly women presenting with acute coronary syn-
drome and who had femoral access for PCI) would be
ideal candidates for protamine administration for
heparin reversal, especially if there are bleeding
events (i.e., hematoma, retroperitoneal bleed).
Rebound thrombogenicity and allergic reactions
to protamine are valid concerns that need to be
addressed. Protamine remains a useful tool in the
armamentarium of interventional cardiologists, and
its judicious use is recommended.*Mandeep Singh, MD, MPH
*Division of Cardiovascular Diseases
Department of Internal Medicine
Mayo Clinic
Rochester, Minnesota 55902
E-mail: singh.mandeep@mayo.edu
http://dx.doi.org/10.1016/j.jacc.2015.06.1337
Please note: Dr. Singh has reported that he has no relationships relevant to the
contents of this paper to disclose.
R EF E RENCE S
1. Singh M. Bleeding avoidance strategies during percutaneous coronary in-
terventions. J Am Coll Cardiol 2015;65:2225–38.
2. Rogers JH, Lasala JM. Coronary artery dissection and perforation compli-
cating percutaneous coronary intervention. J Invasive Cardiol 2004;16:
493–9.
3. De Luca G, Parodi G, Antoniucci D. Safety and beneﬁts of protamine
administration to revert anticoagulation soon after coronary angioplasty: a
meta-analysis. J Thromb Thrombolysis 2010;30:452–8.
4. Cosgrave J, Qasim A, Latib A, Aranzulla TC, Colombo A. Protamine usage
following implantation of drug-eluting stents: a word of caution. Catheter
Cardiovasc Interv 2008;71:913–4.A Proposal to Incorporate
Trial Data Into a Hybrid
AmericanCollegeof Cardiology/
American Heart Association
Algorithm for the Allocation
of Statin Therapy in
Primary Prevention
Ridker et al. (1) draw attention to the importance of
statins as primary prevention agents; they endorse
FIGURE 1 Use of Statins for Primary or Secondary Prevention Based on Initial LDL-C
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The lower the low-density lipoprotein cholesterol level, the fewer the coronary heart
disease (CHD) events and the greater the beneﬁt. Of note is the greater rate of reduction
with secondary events than with primary events.
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1413pharmacological treatment for those patients who
have estimated 10-year risks $7.5% and for whom
trial-based evidence supports statin efﬁcacy. In
addition, the 5-year risk for statin-treated patients
had a relative risk of 0.62 (95% conﬁdence interval:
0.47 to 0.81). Another important point they highlight
is the effect of age (Figure 4 in Ridker et al. [1]). They
warn against overestimation of the 10-year risk,
implying that primary prevention is overused at
present.
There is, however, an alternate way of looking at
indications for the use of statins for primary pre-
vention, on the basis of the initial level of low-
density lipoprotein cholesterol (LDL-C) as shown in
the lower part of Figure 1 (2). This approach shows
that the higher the initial pre-treatment LDL-C level,
the greater the effect of statin therapy and the
greater the reduction in 10-year mortality (Figure 1).
For primary prevention by a statin, a pre-treatment
LDL-C level of 200 mg% (approximately 5 mmol/l)
would substantially reduce the 10-year risk of a
coronary heart disease event, whereas starting
statin therapy at an initial level of 120 mg% would
provide only slight improvement in the reduction of
absolute risk. Thus, the absolute pre-therapy LDL-C
level could be crucial in deciding whether to pre-
scribe a statin.*Lionel H. Opie, MD, DPhil
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